… Philadelphia (Ph) … IFN (recombinant IFN alpha or pegylated IFN alpha-2a) achieved stable
MRs and was associated with high rates of treatment discontinuation in a cohort of 20 chronic …

… Chronic inflammation and a dysregulated immune system … Interferon alpha (IFNα) was first
used for the treatment of MPNs … role of IFNα in the treatment of Ph-negative MPNs through a …

… late 1970s [2]. In the 1980s, cloning and large-scale production of interferon alfa allowed
its … as multiple myeloma [5], hairy cell leukemia [6], chronic myeloid leukemia (CML) [7], and …

… the treatment of polycythemia vera patients. Additionally, rIFN-α2 has been revived for the
treatment of chronic myelogenous leukemia … II trial of pegylated interferon alpha-2b therapy for …

… The translocation t(9; 22), also known as “Philadelphia chromosome” (Ph), leads … chronic
myelogenous leukemia. MPN without this mutation are classified as Philadelphia-negative (Ph …

… international randomised study of interferons and STI571 (IRIS) … the treatment of patients
with chronic-phase chronic myeloid … Ph+ CML patients in the chronic phase diagnosed within 6 …

… as the standard therapy in polycythemia vera (PV) but not in chronic myeloid … Furthermore,
ULK1 as a trigger of IFNa-induced p38 MAPK signaling in Ph + … Chronic myeloid leukemia …

… Cytogenetic relapse was defined by the presence of 2 or more Ph chromosomes within
20 counted metaphases. Toxicities were retrospectively graded based on the “Common …

… IFNα has been used in Ph- MPNs for the last three decades; however, not until 2005 when
the JAK2V617F mutation was discovered in the majority of Ph- MPN patients have studies …

… Another patient with del(5)(q14q33) progressed to secondary acute myeloid leukemia (AML)
with complex karyotypes 8 months after ruxolitinib treatment and 7 years after initial …